# Amphista Therapeutics

Source: https://onco.cc/companies/amphista-therapeutics/  
OnCo record `amphista-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Amphista Therapeutics, based near Cambridge in the UK, designs small molecules that make cancer cells destroy specific proteins using a less common disposal enzyme called DCAF16. Its first drug, for acute myeloid leukaemia, was cleared to start human trials in 2026.

## Summary

Amphista Therapeutics is a Cambridge, UK targeted protein degradation company whose Targeted Glue degraders deploy E3 ligases beyond cereblon, such as DCAF16, chosen for each target. Its lead programme, AMX-883, is an orally bioavailable, selective DCAF16-mediated BRD9 degrader for acute myeloid leukaemia that releases the differentiation block in a broad AML population, shows in vivo efficacy alone and synergy with venetoclax, and received FDA clearance of its IND application in June 2026 as the first BRD9-targeted therapy for AML. An oral SMARCA2 Targeted Glue degrader targets SMARCA4-deficient tumours including non-small cell lung cancer through synthetic lethality, and a pan-TEAD degrader targets Hippo pathway-driven cancers such as mesothelioma and NSCLC; both are preclinical, with data presented at AACR 2026. The company is registered in England and Wales (number 11119959) with its head office at Granta Park, Great Abington, Cambridge.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Cambridge
- Type: biotech
- Website: https://amphista.com/

## Notes

- No financing press release is on the company's current news page (which lists 2026 items only), so funding and investors are empty; the reported 2021 Series B and Merck and Bristol Myers Squibb collaborations were not verified. Founding year not sourced.

## Sources

- Official website: https://amphista.com/
- Pipeline: https://amphista.com/pipeline/
- AMX-883 IND clearance (June 2026): https://amphista.com/amphista-therapeutics-announces-fda-clearance-of-ind-application-for-amx-883-its-lead-targeted-glue-degrader-for-acute-myeloid-leukaemia/

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Epigenetic & Transcriptional Therapy](https://onco.cc/fronts/epigenetics/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/), [Synthetic lethality approaches](https://onco.cc/technologies/synthetic-lethality-approaches/)
- companies: [Novartis Venture Fund](https://onco.cc/companies/novartis-venture-fund/)

---
JSON: https://onco.cc/api/v1/entities/amphista-therapeutics.json